|38.86||+0.6200||+1.62%||Vol 375.67K||1Y Perf 101.03%|
|Apr 22nd, 2021 16:00 DELAYED|
|- -%||- -|
|Target Price||86.00||Analyst Rating||Strong Buy 1.25|
|Potential %||121.31||Finscreener Ranking||★★★ 50.34|
|Insiders Trans % 3/6/12 mo.||-100/-100/-17||Value Ranking||★★★+ 53.18|
|Insiders Value % 3/6/12 mo.||-100/-100/-89||Growth Ranking||★★ 48.07|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-80||Income Ranking||— -|
|Market Cap||1.02B||Earnings Rating||Strong Sell|
|Price Range Ratio 52W %||17.60||Earnings Date||6th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||6th May 2021|
|Estimated EPS Next Report||-1.16|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||457.99K|
|Avg. Monthly Volume||535.35K|
|Avg. Quarterly Volume||817.46K|
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) stock closed at 38.86 per share at the end of the most recent trading day (a 1.62% change compared to the prior day closing price) with a volume of 375.83K shares and market capitalization of 1.02B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 88 people. Arcturus Therapeutics Holdings Inc. CEO is Joseph E. Payne.
The one-year performance of Arcturus Therapeutics Holdings Inc. stock is 101.03%, while year-to-date (YTD) performance is -10.42%. ARCT stock has a five-year performance of 18.12%. Its 52-week range is between 19.45 and 129.71, which gives ARCT stock a 52-week price range ratio of 17.60%
Arcturus Therapeutics Holdings Inc. currently has a PE ratio of -11.50, a price-to-book (PB) ratio of 2.67, a price-to-sale (PS) ratio of 153.76, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -25.83%, a ROC of -30.89% and a ROE of -34.17%. The company’s profit margin is -84.18%, its EBITDA margin is -490.70%, and its revenue ttm is $6.89 Million , which makes it $0.26 revenue per share.
Of the last four earnings reports from Arcturus Therapeutics Holdings Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-1.16 for the next earnings report. Arcturus Therapeutics Holdings Inc.’s next earnings report date is 06th May 2021.
The consensus rating of Wall Street analysts for Arcturus Therapeutics Holdings Inc. is Strong Buy (1.25), with a target price of $86, which is +121.31% compared to the current price. The earnings rating for Arcturus Therapeutics Holdings Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Arcturus Therapeutics Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Arcturus Therapeutics Holdings Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 30.85, ATR14 : 4.89, CCI20 : -32.34, Chaikin Money Flow : -0.07, MACD : -7.30, Money Flow Index : 35.47, ROC : -2.07, RSI : 39.61, STOCH (14,3) : 45.69, STOCH RSI : 1.00, UO : 43.92, Williams %R : -54.31), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Arcturus Therapeutics Holdings Inc. in the last 12-months were: Andrew H. Sassine (Buy at a value of $148 700), Joseph E. Payne (Buy at a value of $63 380), Keith C. Kummerfeld (Buy at a value of $29 997), Padmanabh Chivukula (Sold 70 000 shares of value $4 155 200 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.